Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET. A live audio webcast will be available via the company’s News & Events web page and an archived replay will be accessible for 30 days after the live presentation.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: AVBP -3.47%, TNGX -4.2%, KURA +1.73%, PRAX +1.45%, VIR -0.74%, indicating no clear unified sector direction pre-news for DAWN.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Clinical data update | Positive | +4.2% | Three-year FIREFLY-1 OJEMDA data with efficacy and durability metrics. |
| Nov 18 | Conference participation | Neutral | -3.0% | Announcement of fireside chat at Piper Sandler healthcare conference. |
| Nov 13 | Acquisition announcement | Neutral | -14.4% | Agreement to acquire Mersana Therapeutics via cash plus CVR structure. |
| Nov 10 | Upcoming data presentation | Positive | +4.4% | Planned oral presentation of long‑term OJEMDA data at SNO meeting. |
| Nov 04 | Earnings and guidance | Positive | -0.1% | Q3 2025 results with higher OJEMDA revenue and raised 2025 guidance. |
DAWN has shown positive alignment with strong clinical updates, while earnings and corporate transactions have drawn weaker or negative price reactions.
Over the last few months, DAWN reported multiple milestones. Clinical data from the FIREFLY-1 trial on Nov 24, 2025 and new OJEMDA data announced on Nov 10, 2025 were followed by price gains of 4.23% and 4.42%, respectively. An earnings update on Nov 4, 2025 with higher OJEMDA revenue and raised guidance saw little reaction (-0.14%). The announced Mersana acquisition on Nov 13, 2025 coincided with a -14.41% move. A prior conference-participation notice also saw modest downside.
Market Pulse Summary
This announcement outlines Day One’s planned presentation at the 44th J.P. Morgan Healthcare Conference on January 12, with a webcast and 30-day replay. In recent months, DAWN highlighted strong OJEMDA commercial growth, raised 2025 guidance, and released three-year FIREFLY-1 data, while also announcing a Mersana acquisition. Investors tracking this name typically monitor future clinical updates, integration progress on transactions, and subsequent earnings for more substantive catalysts beyond conference appearances.
AI-generated analysis. Not financial advice.
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time.
A live audio webcast of the presentation will be available by visiting the News & Events section of the Company’s website at www.dayonebio.com. An archived replay of the webcast will be available for 30 days following the live presentation.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™) and DAY301.
Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When will Day One (DAWN) present at the J.P. Morgan Healthcare Conference?
Who from Day One (DAWN) will present at the conference?
How can investors listen to Day One (DAWN) presentation at J.P. Morgan?
Will there be a replay of Day One (DAWN) presentation after the live event?
What time is Day One's (DAWN) webcast for international investors?
Where on Day One's site can I find the J.P. Morgan webcast for DAWN?
